Oncology

Latest News

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Dordaviprone (Modeyso) is now approved to treat recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children.

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

As SCLC continues to pose a therapeutic challenge due to rapid progression and early metastasis, the convergence of immunotherapy and precision radiation holds promise to extend survival and improve outcomes. | Image credit: mi_viri - stock.adobe.com

Chemoimmunotherapy Shows Promise for Limited-Stage SCLC in Real-World Study

By AJMC Contributor

July 29th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

August 7th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 7th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

September 26th 2014

Hypercalcaemia as an Early Cancer Biomarker

A study published in the British Journal of Cancer discovered a correlation between hypercalcaemia and the risk of cancer, specifically in males.

September 26th 2014

ESMO Congress: Researchers Identify Barriers to Drug Access

The researchers identified discrepancies across the globe in patient access to life-saving cures for cancer.

September 26th 2014

A New Drug Delivery Vehicle: Anthrax Bacteria

Having delivered antibody mimics to cancer cells in vitro, the research group at MIT that conducted the research is now working on evaluating the technique in tumors grown in mice.

September 25th 2014

Lung Infections May Hamper Efficacy of FDG-PET

A new retrospective study published in JAMA identified that tuberculosis and certain fungal infections in the lungs could hamper the efficient detection of lung cancer by FDG-PET imaging.

September 25th 2014

Treating Late-Stage Lung Cancer Not Cost-Effective: JTO Study

A prospective study published in The Journal of Thoracic Oncology found that the average cost to screen high-risk individuals for developing lung cancer with low-dose computed tomography plus the average cost of curative intent treatment, like surgery, is lower than the average cost to treat advanced stage lung cancer, which quite rarely results in a cure.

September 24th 2014

Proton Radiation-Yea or Nay?

Controversy over the value of proton beam radiation continues to harass clinicians as the therapy emerges to be extremely useful in some, but not all, cancers. Additionally, payers sometimes refuse to cover treatment costs due to lack of evidence of efficacy.

September 24th 2014

NCI's New Approach With The Exceptional Responder Initiative

With the aim of understanding why some patients respond better to a particular drug, NCI has launched the Exceptional Responders Initiative, to generate molecular profiles of tumors that respond well to a particular treatment.

September 24th 2014

PAD2 Overexpression May Promote Skin Cancer

Research published this month in the journal Cancer Research, found that increased expression of the enzyme PAD2 in young mice could lead to skin tumors that could progress to invasive squamous cell carcinoma.

September 23rd 2014

Folowing AACR, ASCO Supports FDA's Guidance for LDTs

The ASCO statement corroborates the need for regulation of laboratory-developed tests, which are increasingly being used to guide personalized treatment in oncology as well as other therapeutic areas.

September 23rd 2014

Should We Pay Doctors Less for Colonoscopy?

Shivan J. Mehta, MD, MBA Scott Manaker, MD, PhD

Due to existing payment structures and practice patterns for colonoscopy, reducing endoscopist reimbursement may diminish access to and quality of colorectal cancer screening.

September 23rd 2014

Updated International Consensus Guidelines for Advanced Breast Cancer Published

The guidelines have been published in 2 journals: Breast and Annals of Oncology.

September 22nd 2014

Amgen's Blinatumomab Get's Breakthrough Status for ALL

The drug is the first in it's class - an antibody designed to engage 2 different targets simultaneously.

September 22nd 2014

New Graphene Biosensor to Detect Cancer Biomarkers

The biosensor, which can detect the oxidative stress marker 8-hydroxydeoxyguanosine, is 5-times more sensitive than the ELISA test that is commonly used to identify biomarkers.

September 19th 2014

Gilead's Zydelig Receives EU Nod for CLL and FL

The approval in CLL is supported primarily by data from a randomized, placebo-controlled phase 3 trial in combination with rituximab in 220 patients with relapsed CLL who were not able to tolerate standard chemotherapy. The approval in FL, is supported by data from a single-arm phase 2 study (Study 101-09) of Zydelig monotherapy in 125 iNHL patients refractory to rituximab and alkylating-agent-containing chemotherapy.

September 19th 2014

Microbubbles: New Carrier for Chemotherapy Delivery

The study, conducted in pancreatic cancer patients in Norway, was presented at the annual meeting of the International Contrast Ultrasound Society in Chicago.

September 19th 2014

Recurrence of Breast Cancer Years After the Initial Tumor

Marj P. Zimmerman, MS, BSPharm Stanton R. Mehr

September 19th 2014

Cancer Trials Face a Shortage of Teen, Young Adult Enrollees

Surabhi Dangi-Garimella, PhD

September 19th 2014

Draft Statement: Evidence Connecting Diet to Colorectal, Breast Cancer Stronger Than Links to Lung, Prostate

Mary K. Caffrey

September 19th 2014

First PD-1 Inhibitor Approved for Melanoma

Surabhi Dangi-Garimella, PhD

September 19th 2014

AACR Seeks FDA Oversight on LDTs

Surabhi Dangi-Garimella, PhD

September 19th 2014

Immunotherapy Trials Offering Promise in Hard-to-Treat Pancreatic Cancer

September 19th 2014

Patient-Contributed Tumor Genetics Data: A Pathway to Better Drug Development

Yair Benita, PhD Barbara Marino, PhD Aman Bhandari, PhD Roni Zeiger, MD Sachin H. Jain, MD, MBA

September 19th 2014

Moving Beyond BRCA Mutations in Familial Breast Cancer

Surabhi Dangi-Garimella, PhD

September 19th 2014

Breast Cancer Survivorship Programs: More Than a Treatment

Marj P. Zimmerman, MS, BSPharm Stanton R. Mehr

September 19th 2014

Avastin: First Molecule in Nearly a Decade for Metastatic Cervical Cancer

Surabhi Dangi-Garimella, PhD

September 19th 2014

FDA Oversight of Laboratory Developed Tests Essential for Patient Health and Safety

Rep. Louise M. Slaughter, MPH

September 19th 2014

Thyroid Cancer: Increased Incidence or Improved Diagnosis?

Sejal Saraiya, PharmD

September 19th 2014

Oncology Medical Home: Improved Quality and Cost of Care

Surabhi Dangi-Garimella, PhD

September 18th 2014

In The Literature: Ramucirumab Improves OS in Advanced Gastric Cancer Patients

The study, published in Lancet Oncology, found that ramucirumab significantly improved survival by over 2 months.

September 18th 2014

In The Literature: SNP Analysis Identifies New Prostate Cancer Susceptibility Loci

The study, published this week in Nature Genetics, is the product of an international collaboration that has identified 23 new loci that could lead to an increased risk of developing prostate cancer.

...

153 154 155 156 157 158 159 160 161

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions